Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KLK7 | P49862 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.46 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | VCP | P55072 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721907 | 0.80 | CA12 (0.51) | KMT2AKDM4EMEN1GAAMAPT | |
| SCHEMBL13603829 | 0.80 | KDM4E (0.49) | KMT2AKDM4EMEN1GAAMAPK1 | |
| SCHEMBL8787979 | 0.77 | KMT2A (0.58) | KMT2AKDM4EMEN1GAAMAPK1 | |
| SCHEMBL10891266 | 0.76 | KMT2A (0.53) | KMT2AKDM4EMEN1GAAMAPK1 | |
| SCHEMBL17089132 | 0.75 | CA1 (0.45) | KMT2AKDM4EMEN1GAAKLK7 | |
| SCHEMBL5488954 | 0.75 | CA12 (0.51) | KMT2AKDM4EMAPTKLK7RAB9A | |
| SCHEMBL10894406 | 0.74 | KMT2A (0.52) | KMT2AKDM4EMEN1GAAMAPK1 | |
| SCHEMBL10894290 | 0.74 | KMT2A (0.52) | KMT2AKDM4EMEN1GAAMAPK1 | |
| SCHEMBL3867453 | 0.74 | MAPT (0.62) | KMT2AKDM4EMEN1MAPTNPC1 | |
| SCHEMBL20476391 | 0.73 | KMT2A (0.42) | KMT2AKDM4EMEN1GAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4428136-B1 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-26 | — | — | EP | claimed |
| WO-2024189472-A1 | IMPROVED SYNTHETIC METHODS OF MAKING SUBSTITUTED PYRIMIDINE INTERMEDIATES FOR SYNTHESIS OF OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-19 | — | — | WO | claimed |
| EP-4428136-A2 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2024-09-11 | — | — | EP | claimed |
| CN-113038952-B | Improved synthetic methods for preparing fused heterocyclic compounds as orexin receptor modulators | 詹森药业有限公司 | 2024-08-23 | — | — | CN | claimed |
| US-12030887-B2 | Synthetic methods of making fused heterocyclic compounds as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-09 | — | — | US | claimed |
| EP-3880204-B1 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-15 | — | — | EP | claimed |
| US-20220009932-A1 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-13 | — | — | US | claimed |
| EP-3880204-A1 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2021-09-22 | — | — | EP | claimed |
| CN-113038952-A | Improved synthetic process for the preparation of fused heterocyclic compounds as orexin receptor modulators | 詹森药业有限公司 | 2021-06-25 | — | — | CN | claimed |
| WO-2020100011-A1 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-22 | — | — | WO | claimed |
| EP-4428136-B1 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-26 | — | — | EP | disclosed |
| WO-2024189472-A1 | IMPROVED SYNTHETIC METHODS OF MAKING SUBSTITUTED PYRIMIDINE INTERMEDIATES FOR SYNTHESIS OF OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024189472-A1 | IMPROVED SYNTHETIC METHODS OF MAKING SUBSTITUTED PYRIMIDINE INTERMEDIATES FOR SYNTHESIS OF OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-19 | — | — | WO | disclosed |
| EP-4428136-A2 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2024-09-11 | — | — | EP | disclosed |
| CN-113038952-B | Improved synthetic methods for preparing fused heterocyclic compounds as orexin receptor modulators | 詹森药业有限公司 | 2024-08-23 | — | — | CN | disclosed |
| US-20220009932-A1 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-13 | — | — | US | disclosed |
| EP-3880204-A1 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2021-09-22 | — | — | EP | disclosed |
| CN-113038952-A | Improved synthetic process for the preparation of fused heterocyclic compounds as orexin receptor modulators | 詹森药业有限公司 | 2021-06-25 | — | — | CN | disclosed |
| WO-2020100011-A1 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020100011-A1 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030887-B2 | Synthetic methods of making fused heterocyclic compounds as orexin receptor modulators | HCRTR2, HCRTR1, HTR3D | KMT2A 957/4885KDM4E 528/4885MEN1 1926/4885 |
| US-20220009932-A1 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, HTR3D | KMT2A 1074/4885KDM4E 531/4885MEN1 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.